NeOnc Technologies Holdings, Inc. (NTHI)

NGM – Real vaqt narxi. Valyuta: USD

3.50

-0.85 (-19.54%)

Bozor ochiq: Aug 12, 2026, 3:24 PM EDT

4.34

-0.01 (-0.26%)

Oldingi bozordan keyin: Aug 11, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

NeOnc Technologies Holdings, Inc. (NTHI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NeOnc Technologies Holdings, Inc. (NTHI)

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Videolar

No Data

Press-relizlar

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

Search stocks

NeOnc Technologies Holdings, Inc. (NTHI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NeOnc Technologies Holdings, Inc. (NTHI)

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Videolar

No Data

Press-relizlar

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence